Atorvastatin administration is associated with dose-related changes in IGF bioavailability

Ram P. Narayanan; Matthew Gittins; Kirk W. Siddals; Robert L. Oliver; Julie E. Hudson; Anne White; Paul Durrington; Robert R. Davies; Martin Rutter; J. Martin Gibson

doi:10.1530/EJE-12-0844

Atorvastatin administration is associated with dose-related changes in IGF bioavailability

Ram P. Narayanan, Matthew Gittins, Kirk W. Siddals, Robert L. Oliver, Julie E. Hudson, Anne White, Paul Durrington, Robert R. Davies, Martin Rutter, J. Martin Gibson

Research output: Contribution to journal › Article › peer-review

Abstract

Objective: IGF levels, their binding proteins (IGFBPs) and high-dose statin therapy have been linked to the development of diabetes.We aimed to identify whether atorvastatin caused dose-related changes in IGF proteins. Design and methods: We measured IGF1, IGF2, IGFBP1 and IGFBP3 concentrations at baseline, 6 and 12 months in Protection Against Nephropathy in Diabetes with Atorvastatin trial participants with type 2 diabetes randomised to 10 mg (n=59) vs 80 mg (n=60) of atorvastatin (n=119; mean (S.D.): age 64 (10) years; 83% male; HbA1c 61 (10) mmol/mol; blood pressure 131/73 mmHg). Results: Atorvastatin was associated with overall reductions in circulating IGF1, IGF2 and IGFBP3 concentrations (P

Original language	English
Pages (from-to)	543-548
Number of pages	5
Journal	European Journal of Endocrinology
Volume	168
Issue number	4
DOIs	https://doi.org/10.1530/EJE-12-0844
Publication status	Published - Apr 2013

Keywords

Aged
Biological Availability
Diabetes Mellitus, Type 2/ blood/drug therapy
Dose-Response Relationship, Drug
Double-Blind Method
Female
Heptanoic Acids/ administration & dosage
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors/administration & dosage
Insulin-Like Growth Factor Binding Protein 1/ blood
Insulin-Like Growth Factor Binding Protein 3/ blood
Insulin-Like Growth Factor I/ metabolism
Insulin-Like Growth Factor II/ metabolism
Male
Middle Aged
Pyrroles/ administration & dosage

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1530/EJE-12-0844

http://www.eje-online.org/content/168/4/543.full.pdf+html

Cite this

@article{d22f2fa0771e4c5bb59a54d64718207a,

title = "Atorvastatin administration is associated with dose-related changes in IGF bioavailability",

abstract = "Objective: IGF levels, their binding proteins (IGFBPs) and high-dose statin therapy have been linked to the development of diabetes.We aimed to identify whether atorvastatin caused dose-related changes in IGF proteins. Design and methods: We measured IGF1, IGF2, IGFBP1 and IGFBP3 concentrations at baseline, 6 and 12 months in Protection Against Nephropathy in Diabetes with Atorvastatin trial participants with type 2 diabetes randomised to 10 mg (n=59) vs 80 mg (n=60) of atorvastatin (n=119; mean (S.D.): age 64 (10) years; 83% male; HbA1c 61 (10) mmol/mol; blood pressure 131/73 mmHg). Results: Atorvastatin was associated with overall reductions in circulating IGF1, IGF2 and IGFBP3 concentrations (P",

keywords = "Aged, Biological Availability, Diabetes Mellitus, Type 2/ blood/drug therapy, Dose-Response Relationship, Drug, Double-Blind Method, Female, Heptanoic Acids/ administration & dosage, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors/administration & dosage, Insulin-Like Growth Factor Binding Protein 1/ blood, Insulin-Like Growth Factor Binding Protein 3/ blood, Insulin-Like Growth Factor I/ metabolism, Insulin-Like Growth Factor II/ metabolism, Male, Middle Aged, Pyrroles/ administration & dosage",

author = "Narayanan, {Ram P.} and Matthew Gittins and Siddals, {Kirk W.} and Oliver, {Robert L.} and Hudson, {Julie E.} and Anne White and Paul Durrington and Davies, {Robert R.} and Martin Rutter and Gibson, {J. Martin}",

note = "MK Rutter and JM Gibson share senior author position",

year = "2013",

month = apr,

doi = "10.1530/EJE-12-0844",

language = "English",

volume = "168",

pages = "543--548",

journal = "European Journal of Endocrinology",

issn = "0804-4643",

publisher = "BioScientifica",

number = "4",

}

TY - JOUR

T1 - Atorvastatin administration is associated with dose-related changes in IGF bioavailability

AU - Narayanan, Ram P.

AU - Gittins, Matthew

AU - Siddals, Kirk W.

AU - Oliver, Robert L.

AU - Hudson, Julie E.

AU - White, Anne

AU - Durrington, Paul

AU - Davies, Robert R.

AU - Rutter, Martin

AU - Gibson, J. Martin

N1 - MK Rutter and JM Gibson share senior author position

PY - 2013/4

Y1 - 2013/4

N2 - Objective: IGF levels, their binding proteins (IGFBPs) and high-dose statin therapy have been linked to the development of diabetes.We aimed to identify whether atorvastatin caused dose-related changes in IGF proteins. Design and methods: We measured IGF1, IGF2, IGFBP1 and IGFBP3 concentrations at baseline, 6 and 12 months in Protection Against Nephropathy in Diabetes with Atorvastatin trial participants with type 2 diabetes randomised to 10 mg (n=59) vs 80 mg (n=60) of atorvastatin (n=119; mean (S.D.): age 64 (10) years; 83% male; HbA1c 61 (10) mmol/mol; blood pressure 131/73 mmHg). Results: Atorvastatin was associated with overall reductions in circulating IGF1, IGF2 and IGFBP3 concentrations (P

AB - Objective: IGF levels, their binding proteins (IGFBPs) and high-dose statin therapy have been linked to the development of diabetes.We aimed to identify whether atorvastatin caused dose-related changes in IGF proteins. Design and methods: We measured IGF1, IGF2, IGFBP1 and IGFBP3 concentrations at baseline, 6 and 12 months in Protection Against Nephropathy in Diabetes with Atorvastatin trial participants with type 2 diabetes randomised to 10 mg (n=59) vs 80 mg (n=60) of atorvastatin (n=119; mean (S.D.): age 64 (10) years; 83% male; HbA1c 61 (10) mmol/mol; blood pressure 131/73 mmHg). Results: Atorvastatin was associated with overall reductions in circulating IGF1, IGF2 and IGFBP3 concentrations (P

KW - Aged

KW - Biological Availability

KW - Diabetes Mellitus, Type 2/ blood/drug therapy

KW - Dose-Response Relationship, Drug

KW - Double-Blind Method

KW - Female

KW - Heptanoic Acids/ administration & dosage

KW - Humans

KW - Hydroxymethylglutaryl-CoA Reductase Inhibitors/administration & dosage

KW - Insulin-Like Growth Factor Binding Protein 1/ blood

KW - Insulin-Like Growth Factor Binding Protein 3/ blood

KW - Insulin-Like Growth Factor I/ metabolism

KW - Insulin-Like Growth Factor II/ metabolism

KW - Male

KW - Middle Aged

KW - Pyrroles/ administration & dosage

U2 - 10.1530/EJE-12-0844

DO - 10.1530/EJE-12-0844

M3 - Article

VL - 168

SP - 543

EP - 548

JO - European Journal of Endocrinology

JF - European Journal of Endocrinology

SN - 0804-4643

IS - 4

ER -

Atorvastatin administration is associated with dose-related changes in IGF bioavailability

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this